Peripheral biomarkers of oxidative stress and their limited potential in evaluation of clinical features of Huntington's patients

References

• Al-Aubaidy HA, Jelinek HF. (2010). 8-Hydroxy-2-deoxy-guanosine identifies oxidative DNA damage in a rural prediabetes cohort. Redox Rep 15:155–60
   PubMed Web of Science ®Google Scholar
• Andrew SE, Goldberg YP, Kremer B, et al. (1993). The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 4:398–403
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Miyasaki JM. (2012). Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 79:59–603
   Web of Science ®Google Scholar
• Aziz NA, Jurgens CK, Landwehrmeyer GB, et al.; EHDN Registry Study Group. (2009). Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease. Neurology 73:1280–5
   PubMed Web of Science ®Google Scholar
• Borowsky B, Warner J, Leavitt BR, et al. (2013). 8OHdG is not a biomarker for Huntington disease state or progression. Neurology 21:1934–41
   Google Scholar
• Butterfield DA, Howard BJ, La Fontaine MA. (2001). Brain oxidative stress in animal models of accelerated aging and the age-related neurodegenerative disorders, Alzheimer's disease and Huntington's disease. Curr Med Chem 8:815–28
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Bader Lange ML. (2009). Multifuctional roles of enolase in Alzheimer's disease: beyond altered glucose metabolism. J Neurochem 111:915–33
   PubMed Web of Science ®Google Scholar
• Chen CM, Wu YR, Cheng ML, et al. (2007). Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. Biochem Biophys Res Commun 359:335–40
   PubMed Web of Science ®Google Scholar
• Ciancarelli I, Di Massimo C, De Amicis D, et al. (2012). Evidence of redox unbalance in post-acute ischemic stroke patients. Curr Neurovasc Res 9:85–90
   PubMed Web of Science ®Google Scholar
• Di Massimo C, Scarpelli P, Di Lorenzo N, et al. (2006). Impaired plasma nitric oxide availability and extracellular superoxide dismutase activity in healthy humans with advancing age. Life Sci 78:1163–7
   PubMed Web of Science ®Google Scholar
• Eidelberg D, Surmeier DJ. (2010). Brain networks in Huntington's disease. J Clin Invest 121:484–92
   Web of Science ®Google Scholar
• Hersch SM, Gevorkian S, Marder K, et al. (2006). Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG. Neurology 66:250–2
   PubMed Web of Science ®Google Scholar
• Hersch SM, Rosas HD. (2010). Biomarkers to enable the development of neuroprotective therapies for Huntington's disease. In: Lo DC, Hughes RE, eds. Neurobiology of Huntington's disease: applications to drug discovery. Boca Raton (FL): Chemical Rubber Company Press , Chapter 11, 267--83
   Google Scholar
• Klepac N, Relja M, Klepac R, et al. (2007). Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects: a cross-sectional study. J Neurol 254:1676–83
   PubMed Web of Science ®Google Scholar
• Long JD, Matson WR, Juhl AE, et al.; the PREDICT-HD Investigators and Coordinators of the Huntington Study Group. (2012). 8OHdG as a marker for Huntington disease progression. Neurobiol Dis 46:625–34
   PubMed Web of Science ®Google Scholar
• Mahoney FI, Barthel DW. (1965). Functional evaluation: the Barthel Index. Md State Med J 14:61–5
   PubMedGoogle Scholar
• Marangos PJ, Paul SM. (1981). Brain levels of neuron-specific and nonneuronal enolase in Huntington's disease. Neurochem 37:1338–40
   PubMed Web of Science ®Google Scholar
• Montoya A, Bruce Price BH, Menear M, Lepage M. (2006). Brain imaging and cognitive dysfunctions in Huntington's disease. J Psychiatry Neurosci 31:21–9
   PubMed Web of Science ®Google Scholar
• Paulsen JS, Langbehn DR, Stout JC, et al.; Predict-HD Investigators and Coordinators of the Huntington Study Group. (2008). Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 79:874–80
   PubMed Web of Science ®Google Scholar
• Paulsen JS, Long JD, Johnson HJ, et al. (2014). Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study. Front Aging Neurosci 6:78 . doi: 10.3389/fnagi.2014.00078
   PubMed Web of Science ®Google Scholar
• Perluigi M, Fai Poon H, Maragos W, et al. (2005). Proteomic analysis of protein expression and oxidative modification in R6/2 transgenic mice: a model of Huntington disease. Mol Cell Proteomics 4:1849–61
   PubMed Web of Science ®Google Scholar
• Polidori MC, Mecocci P, Browne SE, et al. (1999). Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. Neurosci Lett 272:53–6
   PubMed Web of Science ®Google Scholar
• Reuben DB, Siu AL. (1990). An objective measure of physical function in elderly outpatients. J Am Geriatr Soc 38:1105–12
   PubMed Web of Science ®Google Scholar
• Sassone J, Colciago C, Cislaghi G, et al. (2009). Huntington's disease: the current state of research with peripheral tissues. Exp Neurol 219:385–97
   PubMed Web of Science ®Google Scholar
• Sayre LM, Perry G, Smith MA. (2008). Oxidative stress and neurotoxicity. Chem Res Toxicol 21:172–88
   PubMed Web of Science ®Google Scholar
• Shinozaki K, Oda S, Sadahiro T, et al. (2009). S-100B and neuron-specific enolase as predictors of neurological outcome in patients after cardiac arrest and return of spontaneous circulation: a systematic review. Crit Care [Online]. Available from: http://ccforum.com/content/13/4/R121 [last accessed 22 July 2009]
   PubMed Web of Science ®Google Scholar
• Shoulson I. (1981). Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 31:1333–5
   PubMed Web of Science ®Google Scholar
• Sorolla MA, Reverter-Branchat G, Tamarit J. (2008). Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med 45:667–78
   PubMed Web of Science ®Google Scholar
• Stack EC, Matson WR, Ferrante RJ. (2008). Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants. Ann N Y Acad Sci 1147:79–92
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Langbehn DR, Leavitt BR, et al; TRACK-HD investigators. (2009). Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8:791–801
   PubMed Web of Science ®Google Scholar
• Tinetti ME. (1986). Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc 34:119–26
   PubMed Web of Science ®Google Scholar
• Túnez I, Sánchez-López F, Agüera E, et al. (2011). Important role of oxidative stress biomarkers in Huntington's disease. J Med Chem 54:5602–6
   PubMed Web of Science ®Google Scholar
• Zuccato C, Valenza M, Cattaneo E. (2010). Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 90:905–81
   PubMed Web of Science ®Google Scholar